| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Abstracts of Oak Ridge Posters |
1 University of California, San Francisco, CA;2 Singulex Inc., Berkeley, CA;
aaddress correspondence to this author at: San Francisco General Hospital, San Francisco, CA 94110; fax 415-206-3045, e-mail wualan@labmed2.ucsf.edu)
| The first 20% of the full text of this article appears below. |
The European Society of Cardiology and the American College of Cardiology (ESC/ACC) have redefined the criteria for the diagnosis of acute myocardial infarction, requiring an increase in the concentration of cardiac troponin in the clinical context of myocardial ischemia (1). A subgroup of this committee has recommended that the cutoff concentration be established at the 99th percentile of the reference range, with an acceptable interassay imprecision of 
10% (2). The use of a low troponin cutoff concentration enables the detection of more patients who have minor myocardial damage and are at short-term risk for adverse cardiac events (3). In a study conducted by the IFCC, none of the manufacturers of troponin assays cleared by the Food and Drug Administration in 2004 had a sensitivity for detecting troponin at the 99th percentile with the requisite precision (4). Therefore, troponin assays with higher analytical sensitivity and precision are needed to meet the guidelines of The European Society of Cardiology and the American College of Cardiology.
We examined the analytical performance of the ZeptXTM System (Singulex) assay for cardiac troponin I (cTnI), evaluating its sensitivity, precision, and recovery. We assessed the assay’s clinical performance by comparing assay results for 97 specimens from patients with chest pain with results from the 1st-generation Bayer Centaur cTnI assay. With samples from 88 healthy individuals, we determined the 99th percentile cutoff for the ZeptX assay. We also determined the analytical limit of detection (LoD) across 15 sequential assays and calculated the LoD as the mean value of the zero standard plus 3 SDs from
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  M. Rothman and R. De Palma Delays in angiography may cost lives Heart, November 15, 2009; 95(22): 1815 - 1817. [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Schultze, K. H. Carpenter, F. H. Wians, S. J. Agee, J. Minyard, Q. A. Lu, J. Todd, and R. J. Konrad Longitudinal Studies of Cardiac Troponin-I Concentrations in Serum from Male Sprague Dawley Rats: Baseline Reference Ranges and Effects of Handling and Placebo Dosing on Biological Variability Toxicol Pathol, October 1, 2009; 37(6): 754 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Kavsak, X. Wang, D. T. Ko, A. R. MacRae, and A. S. Jaffe Short- and Long-Term Risk Stratification Using a Next-Generation, High-Sensitivity Research Cardiac Troponin I (hs-cTnI) Assay in an Emergency Department Chest Pain Population Clin. Chem., October 1, 2009; 55(10): 1809 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kavsak, A. R. MacRae, M.-J. Yerna, and A. S. Jaffe Analytic and Clinical Utility of a Next-Generation, Highly Sensitive Cardiac Troponin I Assay for Early Detection of Myocardial Injury Clin. Chem., March 1, 2009; 55(3): 573 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.A. Katus, E. Giannitsis, A.S. Jaffe, and K. Thygesen Higher sensitivity troponin assays: Quo vadis? Eur. Heart J., January 2, 2009; 30(2): 127 - 128. [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Jaffe and F. S. Apple Refining Our Criteria: A Critical Challenge Am J Clin Pathol, January 1, 2009; 131(1): 11 - 13. [Full Text] [PDF]
|
|
|
|
|
|
A. H.B. Wu, S. J. Agee, Q. A. Lu, J. Todd, and A. S. Jaffe Specificity of a High-Sensitivity Cardiac Troponin I Assay Using Single-Molecule-Counting Technology Clin. Chem., January 1, 2009; 55(1): 196 - 198. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow and E. M. Antman Evaluation of High-Sensitivity Assays for Cardiac Troponin Clin. Chem., January 1, 2009; 55(1): 5 - 8. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Eggers, A. S. Jaffe, L. Lind, P. Venge, and B. Lindahl Value of Cardiac Troponin I Cutoff Concentrations below the 99th Percentile for Clinical Decision-Making Clin. Chem., January 1, 2009; 55(1): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H.B. Wu, Q. A. Lu, J. Todd, J. Moecks, and F. Wians Short- and Long-Term Biological Variation in Cardiac Troponin I Measured with a High-Sensitivity Assay: Implications for Clinical Practice Clin. Chem., January 1, 2009; 55(1): 52 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mingels, L. Jacobs, E. Michielsen, J. Swaanenburg, W. Wodzig, and M. van Dieijen-Visser Reference Population and Marathon Runner Sera Assessed by Highly Sensitive Cardiac Troponin T and Commercial Cardiac Troponin T and I Assays Clin. Chem., January 1, 2009; 55(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Middleton, K. George, G. Whyte, D. Gaze, P. Collinson, and R. Shave Cardiac Troponin T Release Is Stimulated by Endurance Exercise in Healthy Humans. J. Am. Coll. Cardiol., November 25, 2008; 52(22): 1813 - 1814. [Full Text] [PDF]
|
|
|
|
|
|
A. E. Schultze, R. J. Konrad, K. M. Credille, Q. A. Lu, and J. Todd Ultrasensitive Cross-species Measurement of Cardiac Troponin-I Using the Erenna Immunoassay System Toxicol Pathol, October 1, 2008; 36(6): 777 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Bonaca and D. A. Morrow Defining a Role for Novel Biomarkers in Acute Coronary Syndromes Clin. Chem., September 1, 2008; 54(9): 1424 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kurz, E. Giannitsis, J. Zehelein, and H. A. Katus Highly Sensitive Cardiac Troponin T Values Remain Constant after Brief Exercise- or Pharmacologic-Induced Reversible Myocardial Ischemia Clin. Chem., July 1, 2008; 54(7): 1234 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Tate, W. Ferguson, R. Bais, K. Kostner, T. Marwick, and A. Carter The determination of the 99th centile level for troponin assays in an Australian reference population Ann Clin Biochem, May 1, 2008; 45(3): 275 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Qiu, E. P. Ferrell, N. Nolan, B. H. Phelps, R. Tabibiazar, D. H. Whitney, and E. A. Nalefski Fluorescence single-molecule counting assays for high-sensitivity detection of cytokines and chemokines. Clin. Chem., November 1, 2007; 53(11): 2010 - 2012. [Full Text] [PDF]
|
|
|
|
|
|
J. Todd, B. Freese, A. Lu, D. Held, J. Morey, R. Livingston, and P. Goix Ultrasensitive Flow-based Immunoassays Using Single-Molecule Counting Clin. Chem., November 1, 2007; 53(11): 1990 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Apple and M. M. Murakami Serum and Plasma Cardiac Troponin I 99th Percentile Reference Values for 3 2nd-Generation Assays Clin. Chem., August 1, 2007; 53(8): 1558 - 1560. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kavsak, A. M. Newman, V. Lustig, A. R. MacRae, G. E. Palomaki, D. T. Ko, J. V. Tu, and A. S. Jaffe Long-Term Health Outcomes Associated with Detectable Troponin I Concentrations Clin. Chem., February 1, 2007; 53(2): 220 - 227. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
